Pasithea Therapeutics Cor... (KTTA)
Pasithea Therapeutics Statistics
Share Statistics
Pasithea Therapeutics has 2.71M shares outstanding. The number of shares has increased by 159.31% in one year.
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | 159.31% |
| Shares Change (QoQ) | 113.61% |
| Owned by Institutions (%) | 0.99% |
| Shares Floating | 2.19M |
| Failed to Deliver (FTD) Shares | 1.44K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 8.71K, so 0.32% of the outstanding shares have been sold short.
| Short Interest | 8.71K |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.4% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is null. Pasithea Therapeutics's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pasithea Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.58, with a Debt / Equity ratio of 0.
| Current Ratio | 6.58 |
| Quick Ratio | 6.58 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.48B |
| Employee Count | 4 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.74% in the last 52 weeks. The beta is 0.59, so Pasithea Therapeutics's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | -78.74% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 3.32 |
| Relative Strength Index (RSI) | 52.43 |
| Average Volume (20 Days) | 2.81M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.25B |
| Net Income | -13.9B |
| EBITDA | -14.25B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -12685.72 |
Balance Sheet
The company has 6.92M in cash and 0 in debt, giving a net cash position of 6.92M.
| Cash & Cash Equivalents | 6.92M |
| Total Debt | 0 |
| Net Cash | 6.92M |
| Retained Earnings | -49.58B |
| Total Assets | 16.06M |
| Working Capital | 6.25M |
Cash Flow
In the last 12 months, operating cash flow was -13.92B and capital expenditures 0, giving a free cash flow of -13.92B.
| Operating Cash Flow | -13.92B |
| Capital Expenditures | 0 |
| Free Cash Flow | -13.92B |
| FCF Per Share | -12702.92 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KTTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for KTTA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 2, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 2, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -5.29 |
| Piotroski F-Score | 1 |